Mifeprex Label Allows Use By Physicians Not Trained In Surgical Abortion
Executive Summary
The Population Council and Danco Labs will conduct a postmarketing safety study to compare outcomes for Mifeprex (mifepristone) patients treated by physicians trained in surgical abortion versus those treated by physicians not trained in abortion.
You may also be interested in...
FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization
Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.
Mifeprex Labeling Change: “Routine” Response To Adverse Events, FDA Says
FDA's decision to strengthen warnings on Danco's Mifeprex (mifepristone) is not a signal that the agency will move to pull the product off the market, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, said Nov. 16
Mifeprex Labeling Change: “Routine” Response To Adverse Events, FDA Says
FDA's decision to strengthen warnings on Danco's Mifeprex (mifepristone) is not a signal that the agency will move to pull the product off the market, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, said Nov. 16